Simplified Onboarding in Adults With Type 2 Diabetes

Eligibility Criteria

• 1. Age at time of consent 18-75 years
• 2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
• 3. Basal-bolus (non-AID pump \& MDI), pre-mix, or basal only users suitable for conversion to AID pump therapy for at least 3 months prior to screening. For basal-bolus and premix users, they must have A1c \<12%. For basal only users must have A1c \>7% and \<12%.
• 4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, or their generic equivalents.
• 5. Participant agrees to provide their own insulin for the duration of the study
• 6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
• 7. Stable doses of weight loss medications over the preceding 4 weeks, and plans to maintain throughout the study, that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
• 8. Willing to wear the system continuously throughout the study
• 9. Participant agrees to provide their own compatible smartphone for use with the Dexcom G6 CGM
• 10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
• 11. Able to read and understand English
• 12. Willing and able to sign the Informed Consent Form (ICF)
• 13. If female of childbearing potential, willing and able to have pregnancy testing
• 1. Use of an AID pump in automated mode up to 90 days prior to screening
• 2. Any medical condition which in the opinion of the Investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
• 3. Arrhythmias or other cardiac conditions confirmed by ECG (within past 30 days) which in the opinion of the Investigator, would put the participant at an unacceptable safety risk
• 4. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
• 5. Any planned surgery during the study which could be considered major in the opinion of the Investigator
• 6. History of more than 1 severe hypoglycemic event in 6 months prior to screening
• 7. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
• 8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
• 9. Use of hydroxyurea
• 10. Has taken systemic steroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
• 11. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
• 12. Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
• 13. Planned international travel during the study
• 14. Participation in another clinical study using an investigational drug or device other than the Omnipod in the 30 days prior to screening or intends to participate during the study period
• 15. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
• 16. Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned